{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:40:52Z","timestamp":1761662452731,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.vaccine.2006.11.057","type":"journal-article","created":{"date-parts":[[2006,12,14]],"date-time":"2006-12-14T07:10:44Z","timestamp":1166080244000},"page":"2180-2186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Safety trial using the Leishmune\u00ae vaccine against canine visceral leishmaniasis in Brazil"],"prefix":"10.1016","volume":"25","author":[{"given":"L.E.","family":"Parra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.P.","family":"Borja-Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.O.P.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.B.","family":"Palatnik-de-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Menz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.11.057_bib1","unstructured":"WHO\/TDR. Seventeenth Programme Report Progress 2003\u20132004. WHO\/Leishmaniasis, pdf 2005; 1 pp. http:\/\/www.who.int\/tdr\/publications\/publications\/pdf\/pr17\/leishmaniasis."},{"key":"10.1016\/j.vaccine.2006.11.057_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4269\/ajtmh.1995.52.287","article-title":"Control of zoonotic visceral leishmaniasis. Is it time to change strategies?","volume":"52","author":"Tesh","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.11.057_bib3","first-page":"85","article-title":"Leishmaniose visceral ou calazar: aspectos epidemiol\u00f3gicos e de controle","volume":"31","author":"Furtado Vieira","year":"1998","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2006.11.057_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4269\/ajtmh.1996.55.125","article-title":"The logic of visceral leishmaniasis control","volume":"55","author":"Dye","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.11.057_bib5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0264-410X(00)00339-X","article-title":"A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante, RN)","volume":"19","author":"Da Silva","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib6","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/S0264-410X(03)00032-X","article-title":"Protection in dogs agaisnt visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK","volume":"21","author":"Ramiro","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib8","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","article-title":"Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum","volume":"23","author":"Rafati","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib9","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.vaccine.2004.11.061","article-title":"Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes","volume":"23","author":"Lemesre","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib10","first-page":"166","article-title":"Phase III randomized double blind clinical trial of the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil","volume":"91","author":"Genaro","year":"1996","journal-title":"Mem Inst Osw Cruz MEMIOC"},{"key":"10.1016\/j.vaccine.2006.11.057_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-3024.1989.tb00676.x","article-title":"Vaccination trial against canine visceral leishmaniasis","volume":"11","author":"Dunan","year":"1989","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2006.11.057_bib12","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2004.03.058","article-title":"Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran","volume":"22","author":"Mohebali","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib13","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective Immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib15","first-page":"547","article-title":"Experimental murine Leishmania donovani infection: immunoprotection by the Fucose Mannose Ligand (FML)","volume":"27","author":"Palatnik de Sousa","year":"1994","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2006.11.057_bib16","first-page":"290","article-title":"The FML vaccine (Fucose\u2013Mannose Ligand) protects hamsters from experimental Kala-Azar. Ci\u00eancia e Cultura","volume":"46","author":"Palatnik de Sousa","year":"1994","journal-title":"J Braz Assoc Adv Sci"},{"key":"10.1016\/j.vaccine.2006.11.057_bib17","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.01.072","article-title":"Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins","volume":"22","author":"Palatnik de Sousa","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib18","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.vaccine.2006.02.034","article-title":"Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis","volume":"24","author":"Oliveira-Freitas","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity","volume":"8","author":"Marciani","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2006.11.057_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.virol.2005.01.042","article-title":"Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant popypeptide containing an N-terminal segment of the spike glycoprotein","volume":"334","author":"Bisht","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.11.057_bib21","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/j.vaccine.2005.01.072","article-title":"A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS21","volume":"23","author":"Slovin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0264-410X(95)98263-A","article-title":"Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces proctetive immune response in Balb\/c mice that are similar to those generated by experimental infection","volume":"13","author":"Hancock","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4049\/jimmunol.148.5.1519","article-title":"Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine","volume":"148","author":"Wu","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.11.057_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/infdis\/171.1.18","article-title":"Formulation of an immunogenic human cytomegalovirus vaccine: Response in mice","volume":"171","author":"Britt","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.11.057_bib25","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0264-410X(02)00052-X","article-title":"Stratified and cryogenically stored (SACS) vaccines, a new concept in emergency foot-and-mouth disease vaccine formulation and storage","volume":"20","author":"Barnett","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0264-410X(98)00486-1","article-title":"Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission","volume":"17","author":"Cox","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0264-410X(91)90261-4","article-title":"Development in foot-and-mouth disease vaccines","volume":"9","author":"Bartleting","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib28","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune\u00ae) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib29","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0264-410X(94)80052-2","article-title":"Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma","volume":"12","author":"Livingston","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib30","first-page":"2783","article-title":"GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21","volume":"55","author":"Helling","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2006.11.057_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite vaccine against Plasmodium falciparum malaria","volume":"9","author":"Stoute","year":"1997","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2006.11.057_bib32","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0264-410X(96)00292-7","article-title":"Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani","volume":"15","author":"Santos","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-2006-958006","article-title":"Haemolytic time course differences between steroid and triterpenoid saponins","volume":"61","author":"Takechi","year":"1995","journal-title":"Planta Med"},{"key":"10.1016\/j.vaccine.2006.11.057_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.11.057_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib36","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/S0264-410X(01)00142-6","article-title":"Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS21","volume":"19","author":"Waite","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib37","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0264-410X(97)00139-4","article-title":"Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity","volume":"15","author":"Ronnberg","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4269\/ajtmh.2001.65.510","article-title":"Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil","volume":"65","author":"Palatnik-de-Sousa","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.11.057_bib39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4269\/ajtmh.1999.61.296","article-title":"The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis","volume":"61","author":"Borja Cabrera","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.11.057_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/BC.2000.009","article-title":"Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants","volume":"381","author":"Oda","year":"2000","journal-title":"Biol Chem"},{"key":"10.1016\/j.vaccine.2006.11.057_bib41","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.addr.2004.02.004","article-title":"Current status and potential application of ISCOMs in veterinary medicine","author":"Morein","year":"2004","journal-title":"Adv Drug Del Rev"},{"key":"10.1016\/j.vaccine.2006.11.057_bib42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-3024.1992.tb00469.x","article-title":"Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture","volume":"14","author":"Schetters","year":"1992","journal-title":"Paras Immunol"},{"key":"10.1016\/j.vaccine.2006.11.057_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.vetpar.2006.01.049","article-title":"Onset and duration of immunity against Babesia canis infection in dogs vaccinated with antigens from culture supernatants","volume":"138","author":"Scheters","year":"2006","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2006.11.057_bib44","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0264-410X(96)00045-X","article-title":"Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine","volume":"14","author":"Ma","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.057_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2460\/javma.1991.198.02.304","article-title":"Focal necrotizing granulomatous panniculitis associates with subcutaneous injections of rabies vaccines in catas and dogs: 10 cases (1988\u20131989)","volume":"198","author":"Hendrick","year":"1991","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2006.11.057_bib46","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2460\/javma.1986.188.10.1174","article-title":"Focal cutaneous vasculitis and alopecia at sites of rabies vaccination in dogs","volume":"188","author":"Wilcock","year":"1986","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2006.11.057_bib47","series-title":"Infectious diseases of dog and cat","first-page":"378","article-title":"Viral, ricketsial and mycoplasmal infections","author":"Greene","year":"1990"},{"key":"10.1016\/j.vaccine.2006.11.057_bib48","unstructured":"UNDP\/World Bank\/WHO. Special Programme for Research and Training in Tropical Diseases (TDR), Malaria transmission blocking vaccines: an ideal public good. UNDP\/World Bank\/WHO. Special programme for Research and Training in Tropical Diseases (TDR), TDR\/RBM\/MAL\/VAC\/2000 1"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06012953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06012953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:15:06Z","timestamp":1759400106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06012953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0264410X06012953"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.11.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety trial using the Leishmune\u00ae vaccine against canine visceral leishmaniasis in Brazil","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.11.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}